서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Publications

Detailed Information

Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44

DC Field Value Language
dc.contributor.authorKang, Jae Seung-
dc.contributor.authorBae, Seyeon Y.-
dc.contributor.authorKim, Hangrae R.-
dc.contributor.authorKim, Yeong Seok-
dc.contributor.authorCho, Byung Joo-
dc.contributor.authorHwang, Young-Il-
dc.contributor.authorPark, Hong Suk-
dc.contributor.authorCho, Daeho J.-
dc.contributor.authorLee, Wang Jae-
dc.contributor.authorHwang, Doukho H.-
dc.contributor.authorKim, Kyungjae J.-
dc.contributor.authorYang, Han-Kwang-
dc.contributor.authorKim, Daejin J.-
dc.date.accessioned2012-07-10T01:13:40Z-
dc.date.available2012-07-10T01:13:40Z-
dc.date.issued2009-12-
dc.identifier.citationCARCINOGENESIS; Vol.30, No.12; 1987-1996ko_KR
dc.identifier.issn0143-3334-
dc.identifier.urihttps://hdl.handle.net/10371/78679-
dc.description.abstractCancer cells metastasize to the other site after escaping from the immune system and CD70, CD44 and vascular endothelial growth factor (VEGF) play important roles in this process. It is recently reported that interleukin (IL)-18 is closely related with the pathogenesis of skin tumor. Therefore, we investigated the role of endogenous IL-18 from stomach cancer on the immune escape mechanism and metastasis via the regulation of CD70, CD44 and VEGF expression. IL-18 and IL-18R expressions were not only investigated on tumor tissues (n = 10), and sera (n = 20) from stomach cancer patients, but also on human stomach cancer cell lines. IL-18 and IL-18R expressions were found on stomach cancer cell lines and tumor tissues. In addition, IL-18 levels were elevated in sera from cancer patients (P < 0.05), compared with sera from normal individuals. Changes in CD70, CD44 and VEGF expression by flow cytometry, immunoblotting and enzyme-linked immunosorbent assay and immune susceptibility by (51)Cr-release assay were investigated, after silencing or neutralization of endogenous IL-18. CD70 expression was increased and it increases immune susceptibility of cancer cells. In contrast, CD44 and VEGF expression was decreased and it suppresses neovascularization and the metastasis of stomach cancer. After inoculation of IL-18 small interfering RNA (siRNA)-transfected stomach cancer cells into Balb/C (nu/nu) mice, regression of tumor mass was determined by measuring of tumor size. And the number and location of metastatic lesions were investigated by hematoxylin and eosin staining. The regression of tumor mass and the suppression of metastasis were observed in the mice, which are injected with IL-18 siRNA-transfected cell lines. Our data suggest that endogenous IL-18 might facilitate stomach cancer cell immune escape by suppressing CD70 and increasing metastatic ability by upregulating CD44 and VEGF.ko_KR
dc.language.isoenko_KR
dc.publisherOXFORD UNIV PRESSko_KR
dc.titleInterleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44ko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor강재승-
dc.contributor.AlternativeAuthor배세연-
dc.contributor.AlternativeAuthor김항래-
dc.contributor.AlternativeAuthor김영석-
dc.contributor.AlternativeAuthor김대진-
dc.contributor.AlternativeAuthor조병주-
dc.contributor.AlternativeAuthor양한광-
dc.contributor.AlternativeAuthor황영일-
dc.contributor.AlternativeAuthor김경재-
dc.contributor.AlternativeAuthor박홍숙-
dc.contributor.AlternativeAuthor황덕호-
dc.contributor.AlternativeAuthor조대호-
dc.contributor.AlternativeAuthor이왕재-
dc.identifier.doi10.1093/carcin/bgp158-
dc.citation.journaltitleCARCINOGENESIS-
dc.description.citedreferenceJiang DF, 2003, PROTEOMICS, V3, P724, DOI 10.1002/pmic.200300411-
dc.description.citedreferenceStraubinger RK, 2003, INFECT IMMUN, V71, P2693, DOI 10.1128/IAI.71.5.2693-2703.2003-
dc.description.citedreferenceDouin-Echinard V, 2003, INT IMMUNOL, V15, P359, DOI 10.1093/intimm/dxg038-
dc.description.citedreferenceFelley CP, 2002, HELICOBACTER, V7, P342-
dc.description.citedreferenceCho DH, 2002, BIOCHEM BIOPH RES CO, V298, P289-
dc.description.citedreferenceKobayashi N, 2002, CLIN EXP IMMUNOL, V129, P446-
dc.description.citedreferenceWolf K, 2002, EUR RESPIR J, V20, P369, DOI 10.1183/09031936.02.00303602-
dc.description.citedreferenceCullen BR, 2002, NAT IMMUNOL, V3, P597, DOI 10.1038/ni0702-597-
dc.description.citedreferenceFera MT, 2002, ANN NY ACAD SCI, V963, P326-
dc.description.citedreferenceKelly JM, 2002, NAT IMMUNOL, V3, P83-
dc.description.citedreferencePark H, 2001, IMMUNOL LETT, V79, P215-
dc.description.citedreferenceKawabata T, 2001, CANCER, V92, P2050-
dc.description.citedreferenceKim JH, 2001, J GASTROEN HEPATOL, V16, P969-
dc.description.citedreferenceWong CK, 2001, CLIN EXP IMMUNOL, V125, P177-
dc.description.citedreferencePark CC, 2001, J IMMUNOL, V167, P1644-
dc.description.citedreferenceDohadwala M, 2001, J BIOL CHEM, V276, P20809-
dc.description.citedreferenceHendriks J, 2000, NAT IMMUNOL, V1, P433-
dc.description.citedreferenceCho D, 2000, CANCER RES, V60, P2703-
dc.description.citedreferenceTakeda K, 2000, J IMMUNOL, V164, P1741-
dc.description.citedreferenceVidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734-
dc.description.citedreferenceWielenga VJM, 2000, ADV CANCER RES, V77, P169-
dc.description.citedreferenceGracie JA, 1999, J CLIN INVEST, V104, P1393-
dc.description.citedreferencePaul P, 1999, PATHOL BIOL, V47, P766-
dc.description.citedreferenceNakata A, 1999, ANTICANCER RES, V19, P4131-
dc.description.citedreferenceSaha N, 1999, ARTHRITIS RHEUM, V42, P1577-
dc.description.citedreferenceCabestre FA, 1999, J REPROD IMMUNOL, V43, P183-
dc.description.citedreferenceChappell DB, 1999, CANCER RES, V59, P59-
dc.description.citedreferenceOkamura H, 1998, ADV IMMUNOL, V70, P281-
dc.description.citedreferenceAgematsu K, 1998, BLOOD, V91, P173-
dc.description.citedreferenceDELCHIER JC, 1998, CURR OPIN GASTROEN, V14, P41-
dc.description.citedreferenceKincade PW, 1997, CURR OPIN CELL BIOL, V9, P635-
dc.description.citedreferenceNaor D, 1997, ADV CANCER RES, V71, P241-
dc.description.citedreferenceTsutsui H, 1996, J IMMUNOL, V157, P3967-
dc.description.citedreferenceWolthers KC, 1996, EUR J IMMUNOL, V26, P1700-
dc.description.citedreferenceGotley DC, 1996, BRIT J CANCER, V74, P342-
dc.description.citedreferenceUshio S, 1996, J IMMUNOL, V156, P4274-
dc.description.citedreferenceHERBST HV, 1996, J PATHOL, V179, P55-
dc.description.citedreferenceOKAMURA H, 1995, NATURE, V378, P88-
dc.description.citedreferenceFERRONE S, 1995, IMMUNOL TODAY, V16, P487-
dc.description.citedreferenceFUCHS CS, 1995, NEW ENGL J MED, V333, P32-
dc.description.citedreferenceTAHARA E, 1995, WORLD J SURG, V19, P484-
dc.description.citedreferenceBLASER MJ, 1995, CANCER RES, V55, P2111-
dc.description.citedreferenceHINTZEN RQ, 1995, J IMMUNOL, V154, P2612-
dc.description.citedreferenceKOBATA T, 1994, J IMMUNOL, V153, P5422-
dc.description.citedreferenceTAHARA E, 1994, EUR J GASTROEN HEPAT, V6, pS97-
dc.description.citedreferenceSCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160-
dc.description.citedreferenceHUBER D, 1992, J IMMUNOL, V148, P277-
dc.description.citedreferenceARUFFO A, 1990, CELL, V61, P1303-
dc.description.citedreferenceMETTLIN C, 1988, GASTRIC CANC, P1-
dc.description.tc2-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

Show Simple Item Record
Find it @ SNU

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share

qrcode
SNS Share